Literature DB >> 12762446

A causal proportional hazards estimator for the effect of treatment actually received in a randomized trial with all-or-nothing compliance.

T Loeys1, E Goetghebeur.   

Abstract

Survival data from randomized trials are most often analyzed in a proportional hazards (PH) framework that follows the intention-to-treat (ITT) principle. When not all the patients on the experimental arm actually receive the assigned treatment, the ITT-estimator mixes its effect on treatment compliers with its absence of effect on noncompliers. The structural accelerated failure time (SAFT) models of Robins and Tsiatis are designed to consistently estimate causal effects on the treated, without direct assumptions about the compliance selection mechanism. The traditional PH-model, however, has not yet led to such causal interpretation. In this article, we examine a PH-model of treatment effect on the treated subgroup. While potential treatment compliance is unobserved in the control arm, we derive an estimating equation for the Compliers PROPortional Hazards Effect of Treatment (C-PROPHET). The jackknife is used for bias correction and variance estimation. The method is applied to data from a recently finished clinical trial in cancer patients with liver metastases.

Entities:  

Mesh:

Year:  2003        PMID: 12762446     DOI: 10.1111/1541-0420.00012

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  32 in total

1.  Semiparametric transformation models for causal inference in time to event studies with all-or-nothing compliance.

Authors:  Wen Yu; Kani Chen; Michael E Sobel; Zhiliang Ying
Journal:  J R Stat Soc Series B Stat Methodol       Date:  2015-03-01       Impact factor: 4.488

2.  Causal proportional hazards models and time-constant exposure in randomized clinical trials.

Authors:  T Loeys; E Goetghebeur; A Vandebosch
Journal:  Lifetime Data Anal       Date:  2005-12       Impact factor: 1.588

3.  Nonparametric inference for assessing treatment efficacy in randomized clinical trials with a time-to-event outcome and all-or-none compliance.

Authors:  Robert M Elashoff; Gang Li; Ying Zhou
Journal:  Biometrika       Date:  2012-03-20       Impact factor: 2.445

4.  Sensitivity Analysis of Per-Protocol Time-to-Event Treatment Efficacy in Randomized Clinical Trials.

Authors:  Peter B Gilbert; Bryan E Shepherd; Michael G Hudgens
Journal:  J Am Stat Assoc       Date:  2013-01-01       Impact factor: 5.033

5.  Causal inference in randomized clinical trials.

Authors:  Cheng Zheng; Ran Dai; Robert Peter Gale; Mei-Jie Zhang
Journal:  Bone Marrow Transplant       Date:  2019-03-26       Impact factor: 5.483

6.  A causal proportional hazards estimator under homogeneous or heterogeneous selection in an IV setting.

Authors:  Ditte Nørbo Sørensen; Torben Martinussen; Eric Tchetgen Tchetgen
Journal:  Lifetime Data Anal       Date:  2019-05-07       Impact factor: 1.588

7.  Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention.

Authors:  Pamela M Murnane; Elizabeth R Brown; Deborah Donnell; R Yates Coley; Nelly Mugo; Andrew Mujugira; Connie Celum; Jared M Baeten
Journal:  Am J Epidemiol       Date:  2015-10-19       Impact factor: 4.897

8.  Instrumental variable with competing risk model.

Authors:  Cheng Zheng; Ran Dai; Parameswaran N Hari; Mei-Jie Zhang
Journal:  Stat Med       Date:  2017-01-08       Impact factor: 2.373

9.  Methods for adjusting for bias due to crossover in oncology trials.

Authors:  K Jack Ishak; Irina Proskorovsky; Beata Korytowsky; Rickard Sandin; Sandrine Faivre; Juan Valle
Journal:  Pharmacoeconomics       Date:  2014-06       Impact factor: 4.981

10.  Latent subgroup analysis of a randomized clinical trial through a semiparametric accelerated failure time mixture model.

Authors:  L Altstein; G Li
Journal:  Biometrics       Date:  2013-02-05       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.